Why Did argenx (NASDAQ:ARGX) Sink 16% Premarket on a Trial Stop, and What Could Happen Next for argenx (NASDAQ:ARGX)?

Vinay Lochav

08 October 2026 11:02 PM AEDT

Why Did argenx (NASDAQ:ARGX) Sink 16% Premarket on a Trial Stop, and What Could Happen Next for argenx (NASDAQ:ARGX)?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

What Are the Main Signals for argenx (NASDAQ:ARGX) Right Now?

About 15.9% was the premarket drop in argenx (NASDAQ:ARGX) to USD 781.00 on October 8, 2026, after an independent committee recommended stopping the Phase 3 UNITY study in Sjögren's disease for futility.
USD 1.516 billion of second quarter 2026 product net sales, up 60% from a year earlier and all from VYVGART, is a commercial base at argenx (NASDAQ:ARGX) that does not depend on Sjögren's disease.
USD 5.2 billion of cash and current financial Assets at June 30, 2026 gives argenx (NASDAQ:ARGX) funding for its other late stage programs, including empasiprubart data guided for the fourth quarter of 2026.
October 22, 2026 is the scheduled date for argenx (NASDAQ:ARGX) third quarter figures, the next chance to hear management discuss the UNITY outcome and plans for its remaining pipeline.

What Did argenx Announced and Why Could It Matter for argenx (NASDAQ:ARGX)?

In a release issued at 7:00 a.m. CET on October 8, 2026 (1:00 a.m. ET), argenx said it will discontinue the Phase 3 UNITY study of efgartigimod SC in adults with moderate to severe Sjögren's disease. An independent data monitoring committee recommended stopping after an interim analysis for futility, meaning the study could not meet its primary endpoint. Chief Medical Officer Luc Truyen indicated that the company was disappointed. management indicated that safety was consistent with the known profile and no new signals appeared. Patient numbers were not disclosed. Although an earlier premarket print showed a smaller fall, As of the premarket quote on October 8, 2026, published market data showed argenx (NASDAQ:ARGX) lower by about 15.9% at USD 781.00.

Why Could a Futility Stop Matters Matter for argenx (NASDAQ:ARGX)?

UNITY randomized patients 1:1 to weekly efgartigimod SC or placebo, with the change in clinESSDAI disease activity score at Week 48 as the primary endpoint. Efgartigimod lowers circulating IgG antibodies, and Sjögren's patients in the trial were anti-Ro/SSA positive, so the idea was to reduce autoantibody driven disease. It does not change approved uses such as generalized myasthenia gravis. A futility stop means interim data suggested the effect would not reach significance, so it ends a potential new indication. Investors price pipeline breadth, which is why a failed indication can move argenx (NASDAQ:ARGX) sharply even when current sales are strong. UNITY toplines had been guided for the second half of 2027.

What Could Still Pressure argenx (NASDAQ:ARGX), and What Comes Next?

The main risk is concentration: all USD 2.813 billion of first half 2026 product sales came from VYVGART, so further trial setbacks matter. The company has not disclosed why efgartigimod missed, and a full analysis will follow database lock. Upcoming dates include third quarter figures on October 22, 2026, EMPASSION topline data for empasiprubart in the fourth quarter of 2026 and ADVANCE-NEXT in primary immune thrombocytopenia in the first half of 2027. Offsetting data came on August 17, 2026, when ALKIVIA in myositis met its primary endpoint in the combined population, though dermatomyositis alone was not significant. Premarket prices can reverse by the open, and no analyst reaction was found at the time of writing.

Where Does drop in argenx (NASDAQ:ARGX) Stand After the Latest Update?

The drop in argenx (NASDAQ:ARGX) reflects a futility stop of the Phase 3 UNITY study in Sjögren's disease, announced on October 8, 2026, which removes a late stage indication from the pipeline. The company reported strong second quarter sales, USD 5.2 billion of cash and positive myositis data in August, so the Business is not defined by this one result. Key open items are the full UNITY analysis, third quarter figures on October 22, 2026, and empasiprubart data in the fourth quarter. Premarket moves are provisional.

What Should Investors Know Next About argenx (NASDAQ:ARGX)?

FAQs

Q:ARGX) Sink 16% Premarket on a Trial Stop?

A: An independent data monitoring committee recommended halting the Phase 3 UNITY study of efgartigimod SC in Sjögren's disease for futility after an interim analysis. Published premarket data on October 8, 2026 showed a fall of about 15.9% toUSD 781.00.

Q:ARGX)?

A: The release addressed only the Sjögren's study and did not discuss current sales. VYVGART is approved for generalized myasthenia gravis and, as VYVGART Hytrulo, chronic inflammatory demyelinating polyneuropathy. Second quarter 2026 product sales wereUSD 1.516 billion, up 60%.

Q:ARGX)?

A: Third quarter 2026 figures are scheduled for October 22, 2026. The company also guided empasiprubart EMPASSION topline data in multifocal motor neuropathy for the fourth quarter of 2026 and ADVANCE-NEXT in primary immune thrombocytopenia for the first half of 2027.

Q:ARGX)?

A: management indicated that safety was consistent with the established efgartigimod profile and that no new safety signals were identified. It plans to analyze the data in depth after the study closes and the database is locked, and share lessons with the Sjögren's community.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.